Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2024
Prioritising pills for the people: getting new medicines on schedule a complex process, by New Zealand Doctor
2 February 2024 - The funding of pharmaceuticals is an issue that often makes its way into news headlines. PHARMAC Director, ...
Posted by Michael Wonder on 15 Sep 2023
Company led submission pilot for early evaluation of non-cancer drugs
13 September 2023 - ACE is conducting a pilot of the company-led submission process for selected non-cancer drugs expecting regulatory approval ...
Posted by Michael Wonder on 12 Sep 2023
Taking a proportionate approach to technology appraisals
12 September 2023 - In 2022, NICE introduced the first phase of a new proportionate approach to technology appraisals. ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 05 Jun 2023
Upcoming improvements to the CADTH reimbursement review process
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
Posted by Michael Wonder on 03 Mar 2023
PHARMAC releases final response to review
3 March 2023 - "There are 30 actions we committed to in the interim response – these are part of ...
Posted by Michael Wonder on 27 Oct 2022
Reference Committee for the health technology assessment policy and methods review
27 October 2022 - On 6 September 2021, the Commonwealth entered into a new Strategic Agreement in relation to reimbursement, ...
Posted by Michael Wonder on 07 Sep 2022
FDA accepts Integral Molecular's letter of intent on membrane proteome array antibody specificity test into ISTAND drug development tools pilot program
7 September 2022 - Integral Molecular has been accepted into the US FDA's ISTAND pilot program. ...
Posted by Michael Wonder on 01 Sep 2022
CADTH launches post-market drug evaluation program
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
Posted by Michael Wonder on 07 Jun 2022
Global expert panel publishes guidance on deliberative processes for health technology assessment
7 June 2022 - Value in Health announced today the publication of guidance regarding the establishment or improvement of deliberative ...
Posted by Michael Wonder on 10 Apr 2022
Health Technology Assessment Review Reference Committee will drive reform to support Australian patients
10 April 2022 - The Health Technology Assessment Review Reference Committee announced (via the Department of Health website) is tasked ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 15 Oct 2021
Updates to the procedure guidance for listing medicines on the PBS
15 October 2021 - The Department has updated Section 5.8 New brand of existing pharmaceutical item submissions (not requiring PBAC consideration) ...
Posted by Michael Wonder on 21 Sep 2021
EU-HTA regulation: methodical preparations for implementation start with IQWiG and G-BA
21 September 2021 - The institute and the G-BA are part of a consortium that is developing the methodological basis ...
Posted by Michael Wonder on 19 Aug 2021
NICE’s health technology assessment methods and processes to be evaluated
19 August 2021 - NICE has launched a public consultation on proposed changes to the way it develops recommendations across ...